TGFB1 and neoplasm: Nonetheless, the TGF‐β/SMAD signalling activity quantified in tumours treated with CAF‐sEVs increased 3.7‐fold compared with vehicle‐treated tumours (Figure 7b,c), supporting the hypothesis of CAF‐sEV‐induced TGF‐β signalling hyperactivation.